Your browser doesn't support javascript.
loading
Therapeutic efficacy and safety of biweekly administration of enfortumab vedotin for urothelial carcinoma.
Nakagawa, Ryunosuke; Izumi, Kouji; Toriumi, Ren; Aoyama, Shuhei; Kamijima, Taiki; Kano, Hiroshi; Makino, Tomoyuki; Naito, Renato; Iwamoto, Hiroaki; Yaegashi, Hiroshi; Kawaguchi, Shohei; Shigehara, Kazuyoshi; Nohara, Takahiro; Mizokami, Atsushi.
Affiliation
  • Nakagawa R; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Izumi K; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Toriumi R; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Aoyama S; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Kamijima T; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Kano H; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Makino T; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Naito R; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Iwamoto H; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Yaegashi H; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Kawaguchi S; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Shigehara K; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Nohara T; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Mizokami A; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
Jpn J Clin Oncol ; 2024 Jul 30.
Article in En | MEDLINE | ID: mdl-39077841
ABSTRACT

OBJECTIVES:

Enfortumab vedotin (EV) is an established pharmacotherapy for metastatic urothelial carcinoma (mUC); however, its adverse events (AEs) cannot be overlooked. The study investigated the efficacy and safety of biweekly EV administration.

METHODS:

Patients with mUC who received EV at our institution were included in the study. Eligible patients were classified into two groups as follows those who received EV on a standard schedule (standard group) and those who received EV on a biweekly schedule (biweekly group); the treatment outcomes and AEs between the two groups were compared.

RESULTS:

Nine and 19 patients were in the standard group and biweekly groups, respectively. The progression-free survival, overall survival, and overall response rate were not significantly different between the two groups. AEs following EV administration, such as decreased appetite (P < .01), pruritus (P < .01), rash maculopapular (P < .01), anemia (P = .04), and liver dysfunction (P = .04), were significantly more frequent in the standard group. Grade 3 or higher AEs, such as pruritus (P = .03) and rash maculopapular (P < .01), were significantly more frequent in the standard group. Furthermore, significantly more patients in the standard group had to be given a reduced dose due to adverse events (P = .02).

CONCLUSIONS:

Biweekly administration of EV may be safer without compromising therapeutic efficacy than the standard schedule.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Jpn J Clin Oncol Year: 2024 Document type: Article Affiliation country: Japan Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Jpn J Clin Oncol Year: 2024 Document type: Article Affiliation country: Japan Country of publication: United kingdom